Sy T, Diallo F B, Diallo Y, Camara M K, Diallo A, Cissoko M, Lontsi G R, Diallo M S
Service de gynécologie-obstétrique, CHU Ignace Deen, Conakry, Guinée.
Med Trop (Mars). 2010 Apr;70(2):141-4.
This purpose of this prospective and descriptive study was to evaluate the utility of a calcium-channel inhibitor, i.e. nifedipine, for management of preterm labor in our work setting in terms of safety and cost-effectiveness in comparison with betamimetics classically used for this indication. Study was carried out over a six-month period in the department of Gynecology-Obstetrics Department of Ignace Deen National Hospital in Conakry, Guinea. Pregnant women meeting the following criteria were included: 28 to 33 weeks of amenorrhea, six days of hospitalization either for preterm labor or for another diagnosis that was associated with the occurrence of preterm labor during hospitalization, and absence of contraindications for tocolysis using nifedipine. A total of 42 women were included. Pregnancy was extended for more than 48 hours after the first dose of nifedipine in 86.8% of cases. Administration of nifedipine failed in 5 cases including one case in which it was necessary to change the tocolytic and 4 cases in which delivery occurred less than 48 hours after the first dose of nifedipine. In 68% of cases, 90 mg of nifedipine were sufficient to stop uterine contractions within 48 hours. In 39.5% of cases, no side effects were observed. Adverse effects in the other cases were dizziness (39.5%) and headache (18.4%). The mean term of delivery was 36 weeks +/- 5 days of amenorrhea with a mean extension of 6.2 weeks. Apgar score was low in 30.5% of the newborns and normal in 69.5%. One newborn (2.8%) died. The results of this study indicate that nifedipine is an effective, economical and safe drug for tocolysis and that it can be used as an alternative to betamimetis in countries with limited resources. An information campaign is needed to promote use of nifedipine as a tocolytic in obstetrical facilities of our country.
这项前瞻性描述性研究的目的是评估钙通道抑制剂硝苯地平在我们的工作环境中用于治疗早产的效用,与传统上用于该适应症的β-拟交感神经药相比,评估其安全性和成本效益。研究在几内亚科纳克里伊格纳西·迪恩国家医院妇产科进行,为期六个月。纳入符合以下标准的孕妇:闭经28至33周,因早产或因住院期间与早产发生相关的其他诊断而住院六天,且无使用硝苯地平进行宫缩抑制的禁忌症。共纳入42名妇女。86.8%的病例在首次服用硝苯地平后妊娠延长超过48小时。5例使用硝苯地平失败,其中1例需要更换宫缩抑制剂,4例在首次服用硝苯地平后不到48小时分娩。68%的病例中,90毫克硝苯地平足以在48小时内停止宫缩。39.5%的病例未观察到副作用。其他病例的不良反应为头晕(39.5%)和头痛(18.4%)。平均分娩孕周为闭经36周±5天,平均延长6.2周。30.5%的新生儿阿氏评分低,69.5%正常。一名新生儿(2.8%)死亡。本研究结果表明,硝苯地平是一种有效、经济且安全的宫缩抑制剂,在资源有限的国家可作为β-拟交感神经药的替代品。需要开展宣传活动,以促进在我国产科机构中使用硝苯地平作为宫缩抑制剂。